Dopa-decarboxylase gene polymorphisms affect the motor response to l-dopa in Parkinson's disease
- 1 February 2014
- journal article
- research article
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 20 (2) , 170-175
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Pharmacological treatment and the prospect of pharmacogenetics in Parkinson’s diseaseInternational Journal Of Clinical Practice, 2011
- The COMT Val158Met polymorphism affects the response to entacapone in Parkinson's disease: A randomized crossover clinical trialAnnals of Neurology, 2010
- Levodopa response in early Parkinson's diseaseMovement Disorders, 2009
- Pharmacokinetics and pharmacodynamics of levodopaMovement Disorders, 2008
- Haplotype analysis indicates an association between the DOPA decarboxylase (DDC) gene and nicotine dependenceHuman Molecular Genetics, 2005
- Genetic polymorphism of catechol‐O‐methyltransferase and levodopa pharmacokinetic–pharmacodynamic pattern in patients with Parkinson's diseaseMovement Disorders, 2005
- The effect of monoamine oxidase B (MAOB) and catechol-O-methyltransferase (COMT) polymorphisms on levodopa therapy in patients with sporadic Parkinson's diseaseActa Neurologica Scandinavica, 2004
- Possible parent‐of‐origin effect of Dopa decarboxylase in susceptibility to bipolar affective disorderAmerican Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2002
- A Double-Blind Pharmacokinetic and Clinical Dose—Response Study of Entacapone as an Adjuvant to Levodopa Therapy in Advanced Parkinson's DiseaseClinical Neuropharmacology, 1996
- Tissue-specific alternative splicing of the first exon generates two types of mRNAs in human aromatic L-amino acid decarboxylaseBiochemistry, 1992